Literature DB >> 25259545

Role of corticosteroids for fatigue in advanced incurable cancer: is it a 'wonder drug' or 'deal with the devil'.

Sriram Yennurajalingam1, Eduardo Bruera.   

Abstract

PURPOSE OF REVIEW: Although corticosteroids are frequently used to palliate cancer-related symptoms, limited published studies are available. This review summarizes recent literature on the impact of corticosteroids on fatigue, its related symptoms, and the role of 'corticosteroid rotation' in improving the corticosteroid-related side-effects. RECENT
FINDINGS: Only two placebo-controlled double-blinded randomized studies on corticosteroid for symptoms that met the inclusion criteria were published recently, despite the criteria being extended beyond 2012 and 2013. These two studies confirm the preliminary data that corticosteroids significantly improve cancer-related fatigue and anorexia with no significant side-effects. However, these studies were of short duration. Long-term use of corticosteroids is not recommended at this time because of the risk of debilitating side-effects and no evidence of its long-term benefits. Recent studies also suggest the possible role of corticosteroid rotation or switching similar to opioid rotation for improvement of these side-effects.
SUMMARY: Recent studies confirm the short-term benefit of corticosteroids for the symptomatic treatment of cancer-related fatigue and anorexia cachexia in advanced incurable cancer. Future studies are needed to determine the optimal dose, type, and the role of corticosteroid rotation so as to optimize long-term efficacy and minimize side-effects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25259545     DOI: 10.1097/SPC.0000000000000093

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  4 in total

1.  A little help from steroids in oncology.

Authors:  Dominique Lossignol
Journal:  J Transl Int Med       Date:  2016-04-14

Review 2.  Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era.

Authors:  Laura Kalfeist; Loïck Galland; Fanny Ledys; François Ghiringhelli; Emeric Limagne; Sylvain Ladoire
Journal:  Cells       Date:  2022-02-22       Impact factor: 6.600

3.  Is Timing of Steroid Exposure Prior to Immune Checkpoint Inhibitor Initiation Associated with Treatment Outcomes in Melanoma? A Population-Based Study.

Authors:  Nikita Nikita; Joshua Banks; Scott W Keith; Andrew Song; Jennifer M Johnson; Melissa Wilson; Swapnil Sharma; Grace Lu-Yao
Journal:  Cancers (Basel)       Date:  2022-03-02       Impact factor: 6.639

4.  Anamorelin combined with physical activity, and nutritional counseling for cancer-related fatigue: a preliminary study.

Authors:  Sriram Yennurajalingam; Karen Basen-Engquist; James M Reuben; Bryan M Fellman; Sanjay Shete; Rama Maddi; Janet L Williams; Rony Dev; David Hui; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2021-07-31       Impact factor: 3.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.